Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapy
2021-005064-22Phase 3Active
- Sponsor
- NewAmsterdam Pharma
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, hypercholesterolemia and cardiac event risk comparing Obicetrapib arm with Placebo arm (2 arms). Primary endpoint: Primary LDL-C change at Day 84. Started Jul 2022; status: active.
02
Drugs
obicetrapib
03
Conditions
dyslipidemiahypercholesterolemiacardiac event risk
Beyond the preview
Go deeper on 2021-005064-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005064-22.